Arrowg+ard Blue Advance PICC

The PICC with Antimicrobial and Antithrombogenic Protection1,2

The Arrowg+ard Blue Advance PICC is designed to protect both internal and external catheter surfaces with chlorhexidine, reducing the risk of these catheter-related complications:

  • Intraluminal thrombotic occlusion2,3
  • Microbial colonization1
  • Phlebitis4
  • Intimal hyperplasia4

Demonstrated a 92% reduction of fibrin sheath accumulation on catheter surfaces at 31 days2

 

99.99% colonization reduction in gram-positive and gram-negative bacterial and fungal pathogens for at least 30 days1

 

Reduced thrombotic intraluminal occlusion as evidenced by 51% reduction in flush pressure to clear thrombus3

 

Visit our Product Catalog to see the Arrowg+ard Blue Advance PICC, including the preloaded PICC for use with the Arrow® VPS Rhythm® Device and the Arrow® VPS G4 Device.


 

Arrowg+ard Blue Advance PICC vs. Unprotected PICCs

In an intravascular in vivo model, Arrowg+ard Blue Advance Protection demonstrated a total of 92% reduction in fibrin sheath when challenged with Staph aureus, as compared to an uncoated PICC control. The Arrowg+ard Blue Advance PICC survived until the end of the study (mean 31 days) with no clinical signs of infection.2

 


Unprotected PICC Control Catheter
Day 5: Highly infected tissue and significant thrombus formation.

 


Arrowg+ard Blue Advance PICC
Day 31: Minimal thrombus formation and absence of microbial colonization.*

References:

  1. In vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

  2. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus: AVAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

  3. As compared to uncoated PICCs, in vitro model measuring flush pressure post exposure to bovine blood: AVER-006376. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

  4. As compared to uncoated PICCs, intravascular ovine model: VAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained.

  5. Rosenbauer KA, Herzer JA. Surface morphology and tensile force at breaking point or different kinds of intravenous catheters before and after usage. Scan Electron Microsc. 1981;(Pt3):125-30.

  6. Collins JL, Lutz RJ. In vitro Study of Simultaneous Infusion of Incompatible Drugs in Multilumen Catheters. Heart & Lung. 1991; 20(3):271-7.

  7. Nifong TP and McDevitt TJ. The effect of catheter to vein ratio on blood flow rates in a simulated model of peripherally inserted central venous catheters. Chest 2011;140;48-53

  8. Grove JR, Pevec WC. “Venous Thrombosis Related to Peripherally Inserted Central Catheters.” Journal of Vascular and Interventional Radiology. 2000; 11: 837-840

  9. Trerotola, S, Stavropoulos, S, Mondschein, J, et al. Triple-lumen peripherally inserted central catheter in patients in the critical care unit: prospective evaluation. Radiology 2010;256(1):312-330

Rx only Contraindication: Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance PICC is contraindicated in the following areas: • Patients with known hypersensitivity to chlorhexidine • In presence of device related infections • In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance, Blue FlexTip, SecondSite, TaperFree, VPS G4, and VPS Rhythm are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks of their respective owners. MC-000752 Rev 1